ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,890,211 | +0.1% | 1,050,394 | +15.0% | 0.01% | +8.3% |
| Q2 2023 | $21,866,949 | +33.2% | 913,025 | +4.7% | 0.01% | +33.3% |
| Q1 2023 | $16,411,981 | +10.9% | 872,050 | -6.2% | 0.01% | 0.0% |
| Q4 2022 | $14,796,835 | -1.2% | 929,277 | +1.4% | 0.01% | -10.0% |
| Q3 2022 | $14,970,952 | +17.3% | 916,398 | +1.3% | 0.01% | +11.1% |
| Q2 2022 | $12,762,593 | -39.8% | 905,013 | +3.4% | 0.01% | -35.7% |
| Q1 2022 | $21,207,043 | +14.4% | 875,122 | +10.2% | 0.01% | +27.3% |
| Q4 2021 | $18,530,000 | +9.3% | 793,900 | -22.2% | 0.01% | -21.4% |
| Q3 2021 | $16,947,000 | -29.8% | 1,020,260 | +3.1% | 0.01% | -30.0% |
| Q2 2021 | $24,141,000 | +53.4% | 989,813 | +62.3% | 0.02% | +42.9% |
| Q1 2021 | $15,733,000 | +4.0% | 609,810 | +115.5% | 0.01% | 0.0% |
| Q4 2020 | $15,125,000 | +397.2% | 282,915 | +292.9% | 0.01% | +366.7% |
| Q1 2020 | $3,042,000 | +11.2% | 72,006 | +12.6% | 0.00% | 0.0% |
| Q4 2019 | $2,735,000 | +12.8% | 63,932 | -3.1% | 0.00% | 0.0% |
| Q3 2019 | $2,425,000 | +37.4% | 65,945 | -0.1% | 0.00% | +50.0% |
| Q2 2019 | $1,765,000 | -11.3% | 66,024 | -10.9% | 0.00% | 0.0% |
| Q1 2019 | $1,990,000 | +101.6% | 74,138 | +21.4% | 0.00% | +100.0% |
| Q4 2018 | $987,000 | +65.3% | 61,056 | +112.2% | 0.00% | 0.0% |
| Q3 2018 | $597,000 | -47.8% | 28,774 | -61.5% | 0.00% | 0.0% |
| Q2 2018 | $1,143,000 | -62.9% | 74,814 | -45.4% | 0.00% | -66.7% |
| Q1 2018 | $3,078,000 | +2443.8% | 136,980 | +3295.6% | 0.00% | – |
| Q4 2017 | $121,000 | -26.7% | 4,034 | -7.9% | 0.00% | – |
| Q3 2017 | $165,000 | +275.0% | 4,380 | 0.0% | 0.00% | – |
| Q2 2017 | $44,000 | -66.9% | 4,380 | +13.4% | 0.00% | – |
| Q1 2017 | $133,000 | +33.0% | 3,863 | +10.8% | 0.00% | – |
| Q4 2016 | $100,000 | -9.9% | 3,485 | 0.0% | 0.00% | – |
| Q3 2016 | $111,000 | +11.0% | 3,485 | +12.7% | 0.00% | – |
| Q2 2016 | $100,000 | -95.4% | 3,092 | -96.3% | 0.00% | -100.0% |
| Q1 2016 | $2,187,000 | -31.2% | 84,083 | -5.7% | 0.00% | -33.3% |
| Q4 2015 | $3,177,000 | +2.7% | 89,126 | -4.7% | 0.00% | 0.0% |
| Q3 2015 | $3,092,000 | -58.8% | 93,511 | -47.8% | 0.00% | -66.7% |
| Q2 2015 | $7,498,000 | +340.5% | 179,035 | +242.9% | 0.01% | +350.0% |
| Q1 2015 | $1,702,000 | +6.1% | 52,205 | +3.4% | 0.00% | 0.0% |
| Q4 2014 | $1,604,000 | +25.5% | 50,510 | -2.1% | 0.00% | 0.0% |
| Q3 2014 | $1,278,000 | +11.6% | 51,616 | +1.9% | 0.00% | 0.0% |
| Q2 2014 | $1,145,000 | -11.9% | 50,664 | -5.2% | 0.00% | 0.0% |
| Q1 2014 | $1,300,000 | -3.1% | 53,440 | -0.5% | 0.00% | 0.0% |
| Q4 2013 | $1,342,000 | -10.6% | 53,687 | -1.7% | 0.00% | -33.3% |
| Q3 2013 | $1,501,000 | +50.6% | 54,622 | -0.5% | 0.00% | +50.0% |
| Q2 2013 | $997,000 | – | 54,924 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |